Jonathan D Bender, Helen Oquendo-Del Toro, Janie Benoit, Jonathan C Howell, Priscila Badia, Stella M Davies, Michael S Grimley, Sonata Jodele, Christine Phillips, Karen Burns, Rebecca Marsh, Adam Nelson, Gregory Wallace, Christopher E Dandoy, Abigail Pate, Andrew C Strine, Olivia Frias, Lesley Breech, Susan R Rose, Holly Hoefgen, Pooja Khandelwal, Kasiani C Myers
BACKGROUND: Hematopoietic stem cell transplant (HSCT) is a curative therapy for many pediatric malignancies and non-malignant conditions. Gonadal insufficiency or infertility is present in almost all survivors of myeloablative conditioning (MAC). Reduced intensity conditioning (RIC) regimens are being increasingly used in medically fragile patients or in patients with non-malignant diagnoses to limit the toxicities associated with HSCT, however the short and long-term gonadal toxicity of RIC remains unknown in pediatric and young adult survivors...
October 30, 2022: Transplantation and cellular therapy